Using 68GA-labeled CD73 Targeting Probe PETCT Imaging to Diagnose Malignant Tumors and Guide Treatment

What this Trial Is About

Researchers are evaluating the use of 68GA-DOTA-dPNE PETCT imaging to observe how this tracer binds to lesions in patients with malignant tumors. This study aims to assess the expression of CD73 in these tumors and explore the tracers potential in diagnosing malignant tumors, guiding treatment, and predicting responses to targeted therapy. The study is interventional and involves adults aged 18 to 70 years with malignant tumors. Participants will receive an intravenous injection of the 68GA-DOTA-dPNE tracer during the PETCT imaging procedure. This imaging helps visualize tumor lesions and measure tracer uptake. The study does not involve any placebo or comparison group but focuses on evaluating the tracers behavior in malignant tumor patients. The treatment and imaging occur in a controlled clinical setting. During the study, researchers will measure the lesion SUV value immediately after the PET scan to evaluate tracer uptake. Participants must provide written informed consent and be able to follow up as required. The study excludes individuals with severe liver or kidney dysfunction, those who cannot lie flat for 30 minutes, or individuals with claustrophobia or certain mental illnesses. Women who are pregnant, breastfeeding, planning pregnancy, or not using effective contraception are also excluded. The trial will end by March 30, 2026, with participation lasting through the imaging and follow-up period as needed.

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor